Anju Wadhwa, Sinan Wang, Bonell Patiño-Escobar, Anil P Bidkar, Kondapa Naidu Bobba, Emily Chan, Niranjan Meher, Scott Bidlingmaier, Yang Su, Suchi Dhrona, Huimin Geng, Vishesh Sarin, Henry F VanBrocklin, David M Wilson, Jiang He, Li Zhang, Veronica Steri, Sandy W Wong, Thomas G Martin, Youngho Seo, Bin Liu, Arun P Wiita, Robert R Flavell
PURPOSE: Multiple myeloma (MM) is a plasma cell malignancy with an unmet clinical need for improved imaging methods and therapeutics. Recently, we identified CD46 as an overexpressed therapeutic target in MM and developed the antibody YS5, which targets a cancer-specific epitope on this protein. Herein, we validate [89Zr]Zr-DFO-YS5 for immunoPET imaging and [225Ac]Ac-DOTA-YS5 for radiopharmaceutical therapy of MM in murine models. EXPERIMENTAL DESIGN: In vitro saturation binding was performed using the CD46 expressing MM...
December 18, 2023: Clinical Cancer Research